Related Experiment Videos
Withdrawal of parenteral phenobarbitone--implications for resource-poor countries
J M Wilmshurst1, Ronald van Toorn, C R J C Newton
1Division of Paediatric Neurosciences and Child Development, Red Cross Children's Hospital and University of Cape Town. wilmshur@ich.uct.ac.za
Summary
Parenteral phenobarbitone is a safe and effective first-line treatment for status epilepticus, especially in resource-limited settings. Its loss would lead to poorer seizure control, increased complications, and strain on healthcare resources.
Area of Science:
- Pediatric Neurology
- Emergency Medicine
- Pharmacology
Background:
- Status epilepticus (SE) is a medical emergency requiring prompt treatment.
- Parenteral phenobarbitone is a critical anticonvulsant, particularly in resource-limited settings.
- Concerns exist regarding the availability and alternatives to parenteral phenobarbitone.
Purpose of the Study:
- To highlight the importance of parenteral phenobarbitone in managing status epilepticus.
- To discuss the implications of its potential loss from clinical practice.
- To emphasize its safety, efficacy, and cost-effectiveness.
Main Methods:
- Review of existing literature and clinical guidelines on status epilepticus management.
- Analysis of the properties of parenteral phenobarbitone versus proposed alternatives.
- Assessment of the potential consequences of phenobarbitone withdrawal.
Main Results:
- Parenteral phenobarbitone is highly effective, safe, and cost-efficient for seizure control in SE.
- It is recommended by Advanced Paediatric Life Support guidelines.
- Alternatives often lack efficacy, practicality, or pose risks like respiratory compromise.
Conclusions:
- The loss of parenteral phenobarbitone would significantly worsen outcomes for children with SE.
- This includes increased morbidity, mortality, and healthcare system burden.
- Maintaining access to parenteral phenobarbitone is crucial for effective SE management globally.